research Ruxolitinib for the treatment of severe alopecia areata
Ruxolitinib can help regrow hair in severe alopecia areata.
Search
for
Sort by
Research
360-390 / 1000+ results 
research Remarkable Improvement of Nail Changes in Alopecia Areata Universalis with 10 Months of Treatment with Tofacitinib: A Case Report
A man with severe hair loss saw hair and nail improvement after 10 months on tofacitinib without side effects.
research Tofacitinib in alopecia areata and HIV: A curious intersection of immunomodulation, hair regrowth, and hypertrichosis
Tofacitinib can cause unusual hair growth, requiring careful monitoring and possible laser hair removal.
research Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
research Rapid generation of homogenous tumor spheroid microtissues in a scaffold-free platform for high-throughput screening of a novel combination nanomedicine
A new triple drug system using nanoparticles effectively targets breast tumors in 3D models.
research Arthritis drug spurs hair regrowth in alopecia patient
An arthritis drug helped a person with severe hair loss regrow their hair.
research BH08 Unprovoked pulmonary emboli in a patient with alopecia areata treated with ritlecitinib: a case report
Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.
research Nilotinib-induced generalized keratosis pilaris: Report of a rare case
Nilotinib can cause generalized keratosis pilaris.
research New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics
New drugs and therapies targeting specific pathways show promise in treating advanced prostate cancer.
research Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature
Tofacitinib helped psoriasis but not alopecia universalis, needing more research.
research Efficacy and safety of tofacitinib in pediatric patients with alopecia areata: A prospective cohort study
Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.
research Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B
research Ritlecitinib in Alopecia Areata: A 24‐Week Real‐World Experience Contrasting JAK Inhibitor‐Naïve and JAK Inhibitor‐Experienced Patients
Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.
research S-1 induced discoid lupus erythematosus-like lesions and long-term complete response for para-aortic lymph node recurrence of pancreatic ductal adenocarcinoma: a case report
S-1 treatment led to a complete response in pancreatic cancer with manageable side effects.
research Supplementary file 1_Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.docx
Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.
research Topical tofacitinib in treatment of alopecia areata
Topical tofacitinib shows promise as a future treatment for alopecia areata.
research Hair today, gone tomorrow
Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.
research Efficacy and safety of tofacitinib therapy in Asian patients with severe alopecia areata
Tofacitinib helps regrow hair in severe alopecia patients, but more research is needed.
research Topical Application of Aprepitant Inhibits Erlotinib-induced Facial Dermatitis/Hair Loss
Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.
research Circumscribed Alopecia Areata Incognita and Response to Tofacitinib
Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.
research Population exposure–response analysis of the effect of ritlecitinib on eyebrow assessment and eyelash assessment in patients with alopecia areata
Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.
research The usefulness and wellbeing of Tofacitinib in the treatment of Alopecia Areata
Tofacitinib is effective and safe for treating alopecia areata.
research Slow progress in prostate cancer
Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.
research Alopecia areata flare patterns in children and young adults while on systemic tofacitinib
Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.
research Using patient preference to inform ritlecitinib dose selection for alopecia areata treatment
Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
research Abstract P5-09-21: Selective androgen receptor modulators (SARMs): Enobosarm as targeted therapy for the treatment of androgen receptor-positive breast cancer
Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.
research Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO ‐2b/3 and ALLEGRO ‐ LT Clinical Studies for Alopecia Areata
Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
research Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
Tofacitinib may be safe and effective for treating certain skin conditions in children.
research Baricitinib-Induced Remission of Alopecia Universalis in a Child with NFKB2-Associated Immune Dysregulation
research Safety and efficacy of tofacitinib in 97 alopecia areata patients
Tofacitinib is an effective and safe treatment for alopecia areata.